Abstract. CXXC5 is a newly identified CXXC-type zinc finger family protein, which is encoded by the CXXC5 gene localised to the 5q31.3 chromosomal region. Previous studies revealed that CXXC5 is associated with various malignant tumours. The aim of the present study was to investigate the prognosis prediction of CXXC5 in different breast cancer subtypes via the Gene Expression Omnibus database and bc-GenExMiner. CXXC5 overexpression was observed as associated with a poor prognosis for oestrogen receptor positive (ER+) breast cancer. Basal-like breast cancer and triple-negative breast cancer also suggest a poor prognosis, however their CXXC5 expression was low and could not be used as a prognostic factor. The CXXC5 correlated genes and their enriched Gene Ontology (GO) terms were obtained. Among those enriched GO terms, GO:0070062 (extracellular exosome) had the greatest number of associated genes and the associated genes of GO:0000122 (negative regulation of transcription from RNA polymerase II promoter) and GO:0008134 (transcription factor binding) contained CXXC5. These results suggest that overexpression of CXXC5 is a strongly poor prognostic factor in ER+ breast cancer. However, the role of CXXC5 in breast cancer requires further investigation.
Introduction
Breast cancer is one of the most common malignant tumours among women (1) . There were precise data from 2012 related to breast cancer incidence and mortality. Across 5 years, from 2008 to 2012, the average incidence rates for white women were the highest, followed by those of black women (2, 3) . The current 5-year survival rate of primary breast cancer is relatively high, ranging from 80 to 92% in different populations (4) . However, it decreases to <25% when the disease becomes metastatic (4, 5) . The most important factor to improve the survival rate of patients is to find the most effective treatment, which is guided by tumour cell characteristics (6, 7) . Once a metastatic lesion is found, accurate characterisation of the tumour cells must be obtained at the start of treatment (8) ; a possible way to do this is the use of biomarkers (9) . Currently, a series of different biomarkers, such as tissue markers, genetic markers, serum markers and non-coding RNA (1, 10, 11) , have been found, but it is much more difficult to assess the effectiveness of the targeted treatment or prognosis of the disease. Therefore, we need to find more biomarkers and determine their clinical utility in future research (9) .
CXXC finger protein 5 (CXXC5) is a protein encoded by the CXXC5 gene localised to the 5q31.3 chromosomal region, which is often deleted in myeloid leukaemia (12) . Kühnl et al (13) reported that CXXC5 could suppress progression of acute myeloid leukaemia (AML) via inhibiting the Wnt pathway and that downregulation of CXXC5 could predict a better prognosis in AML. The study of Bruserud et al (14) showed that high CXXC5 expression was related to the stem cell signature of AML that has a bad prognostic impact. We know that 17β-oestradiol (E2) plays an important role in the homeodynamic regulation of breast tissue functions, and the oestrogen receptor (ERα) is the primary transcript expressed in breast tissue. Yasar et al (15) reported that E2-ERα could regulate the expression of CXXC5. Therefore, we knew that there was a certain relationship between CXXC5 and breast cancer. Knappskog et al (16) reported that the overexpression of CXXC5 was significantly associated with a bad prognosis in breast cancer. However, the prognostic implications of CXXC5 expression in breast cancers of different molecular types remain unclear. In our study, we used Breast Cancer Gene-Expression Miner v4.0 (bc-GenExMiner v4.0, bcgenex. centregauducheau.fr/BC-GEM/GEM-Accueil.php?js=1) (17) , a database that includes a total of 5,861 patients, as the main tool to analyse the role of CXXC5 expression in different breast cancer subtypes. We aimed to show that CXXC5 expression predicts the prognosis of different breast cancer subtypes.
Materials and methods

GEO data analysis.
We obtained the dataset of GDS5666 (18) from Gene Expression Omnibus (GEO; https://www.ncbi.nlm. nih.gov/geo/) (19) and analysed it using the Data Analysis Tools of DATASET BROWSER in GEO. Probes of A_51_P234788 (ID_REF) and A_52_P633393 (ID_REF) represented the CXXC5 gene in the platform of GPL7202. We obtained 2 sets of CXXC5 mRNA expression values from these probes. We used the average value of each sample's CXXC5 mRNA expression as the expression value for that sample. 
Bioinformatics
Results
CXXC5 expression is increased in 4T1-derived metastatic cancer compared to primary cancer.
We observed that the expression values of CXXC5 were higher in 4T1-derived metastatic populations than in primary cancers (Fig. 1A) . Then, we used bc-GenExMiner v4.0 to determine that CXXC5 upregulation with metastatic relapse (MR) or AE was associated with a poor prognosis of breast cancer ( Fig. 1B and C) . In the PAM50 breast cancer subtypes, the basal-like subtype had the lowest CXXC5 expression, and CXXC5 expression of luminal tumours was higher than in other types ( Fig. 1D ).
High level of CXXC5 is a poor prognostic factor in oestrogen receptor positive (ER+) breast cancer.
The impact of CXXC5 in breast cancer was considered robust because there were 10 significant results (P<0.05) among the 18 given results (Table I) . We determined that the high level of CXXC5 expression is associated with poor prognosis of breast cancer with Nm/ER+/AE, Nm/ER+/MR, N+/ER+/AE, N-/ER+/MR, N+/ER+/MR, Nm/ERm/MR, Nm/ERm/AE, N+/ERm/AE, N+/ER-/AE and N-/ER+/AE through CXXC5 univariate Cox analysis (Table I) . In particular, all breast cancer patients with ER+ status had a poor prognosis. CXXC5 expression was significantly higher in ER+ breast cancer than in ER-breast cancer ( Fig. 2A) . Using the Kaplan-Meier curve, we ascertained that high CXXC5 expression predicted significantly poor AE-free survival in Nm/ER+ status (HR=1.50; 95% CI, 1.31-1.73; P<0.0001) (Fig. 2B) , MR-free survival in Nm/ER+ status (HR=1.70; 95% CI, 1.37-2.10; P<0.0001) (Fig. 2C) , AE-free survival in N+/ER+ status (HR=1.51; 95% CI, 1.21-1.87; P=0.0002) (Fig. 2D) , MR-free survival in N-/ER+ status (HR=1.56; 95% CI, 1.06-2.27; P= 0.0228) (Fig. 2E) and MR-free survival in N+/ER+ status (HR=1.59; 95% CI, 1.16-2.20; P=0.0042) (Fig. 2F) . However, CXXC5 expression could not predict AE-free survival in N-/ER+ status (P=0.0763) (Fig. 2G) .
Basal-like breast cancer and/or TNBC prognostic analysis for CXXC5. The basal-like breast cancer had lower CXXC5 expression than other subtypes (Fig. 1D) . However, basal-like breast cancer could predict bad prognosis, as 75-80% of the triple-negative breast cancers (TNBC) belonged to the group of basal-like breast cancer (20) . High levels of CXXC5 expression could predict a bad prognosis in TNBC with MR via CXXC5 univariate Cox analysis (basal-like and/or TNBC) but not in the other group (Tables II and III) . However, CXXC5 expression was not associated with prognosis of TNBC with MR through the Kaplan-Meier curve analysis (Fig. 3A) . Consistent with the results of CXXC5 univariate Cox analysis (basal-like and/or TNBC), CXXC5 expression was not associated with the prognosis of breast cancer in the other groups ( Fig. 3B-F ).
Correlated genes with CXXC5. We obtained the correlated genes with CXXC5 in breast cancer through gene correlation exhaustive analysis. Table IV shows the top 10 best positive/negative correlations with CXXC5. Then, we obtained the GO enrichments of the correlated genes with CXXC5 via GO analysis of bc-GenExMiner v4.0 (Table V) . Among them, GO:0070062 (extracellular exosome) had the most associated genes, and the associated genes of both GO:0000122 (negative regulation of transcription from RNA polymerase II promoter) and GO:0008134 (transcription factor binding) contained CXXC5.
Discussion
CXXC5 is a newly identified CXXC-type zinc finger family protein (21) , which is encoded by the CXXC5 gene localised to the 5q31.3 chromosomal region (12) . Previous studies showed that CXXC5 was related to AML, myelodysplastic syndromes, human malignant peripheral nerve sheath tumours, prostate cancer, breast cancer, thyroid cancers and metastatic melanomas (16, (22) (23) (24) (25) . Knappskog et al (16) used three independent public microarray datasets, including 599 patients from GEO, to find that CXXC5 was a bad prognostic factor in breast cancer. However, they did not study the effects of CXXC5 on various subtypes in breast cancer.
In our study, using the dataset of GDS5666 from GEO, we found that the expression of CXXC5 was higher in 4T1-derived metastatic populations than in primary breast cancers. Therefore, CXXC5 might be associated with metastasis. Then, we used expression analysis of bc-GenExMiner v4.0 to find that the expression of CXXC5 was significantly different in PAM subtypes. We established that the high level of CXXC5 expression is associated with poor prognosis of ER+ breast cancer through CXXC5 univariate Cox analysis and Kaplan-Meier curve analysis of bc-GenExMiner v4.0. These results propose CXXC5 as a biomarker and potential therapeutic target in ER+ breast cancer. Although basal-like breast cancer and TNBC could predict bad prognosis, their CXXC5 expression was low. In addition, CXXC5 could not predict their prognosis. Finally, we obtained the CXXC5 correlated genes and enriched GO terms of those genes through gene correlation exhaustive analysis of bc-GenExMiner v4.0. Among those enriched GO terms, GO:0070062 (extracellular exosome) had the most associated genes, and the associated genes of both GO:0000122 (negative regulation of transcription from RNA polymerase II promoter) and GO:0008134 (transcription factor binding) contained CXXC5. These GO terms can guide new investigations into understanding the mechanisms of CXXC5 in breast cancer and propose new treatments for ER+ breast cancer.
There is a limitation to the present study. The mechanism of CXXC5 in breast cancer requires further investigation via in vitro and in vivo experiments.
In conclusion, we determined that overexpression of CXXC5 was a strongly poor prognostic factor in ER+ breast cancer through the tools of bc-GenExMiner V4.0 based on a database including a total of 5,861 patients. This means that regardless of the clinical stage of breast cancer, high expression of CXXC5 in patients predicts that the disease is more significantly invasive. As is known, gene expression can be measured in many ways. We hope that measuring the expression of CXXC5 may become a routine inspection to assess the prognosis of breast cancer in different patients. In this way, early intervention and treatment could be used, and the survival rate of patients could improve. However, the pathways of CXXC5 in breast cancer require further investigation. If in-depth research is conducted, we may find the pathways of CXXC5 in breast cancer, and then CXXC5 can be utilized as a potential therapeutic target.
